SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022

20 окт 2022 16:20:54 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)

29 сен 2022 07:30:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting

28 сен 2022 07:30:00 Источник Nasdaq GlobeNewswire

Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting

16 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®

13 сен 2022 02:01:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

02 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

25 авг 2022 15:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy

23 авг 2022 07:03:39 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

16 авг 2022 07:01:00 Источник Nasdaq GlobeNewswire

Sight Sciences Reports Second Quarter 2022 Financial Results

11 авг 2022 15:05:02 Источник Nasdaq GlobeNewswire

Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

28 июл 2022 07:00:02 Источник Nasdaq GlobeNewswire

Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

19 июл 2022 15:26:27 Источник Nasdaq GlobeNewswire

Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data

31 май 2022 07:00:01 Источник Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium

19 май 2022 07:00:00 Источник Nasdaq GlobeNewswire

Sight Sciences Reports First Quarter 2022 Financial Results

10 май 2022 15:05:02 Источник Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

29 апр 2022 07:00:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

20 апр 2022 15:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022

14 апр 2022 15:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results

24 мар 2022 15:05:01 Источник Nasdaq GlobeNewswire

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

24 мар 2022 15:04:00 Источник Nasdaq GlobeNewswire